Latest Commercialization News

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

Galan Lithium Limited has announced a substantial 150% increase in its Candelas Mineral Resource to 1.6 Mt LCE, lifting its total Hombre Muerto West resource to 9.5 Mt LCE and securing a spot among the world’s top 10 lithium projects.

CurveBeam AI Limited reported a remarkable 150% increase in device purchase orders in Q2 FY25, driven by strong demand for its HiRise™M platform and a new commercial agreement with Stryker. The company is advancing validation of its Enhanced HiRise™ for robotic surgical systems, despite a regulatory delay for its BMD SaaS module.

CurveBeam AI has reported a record quarter for HiRise™ device purchase orders, driven by a strategic expansion with Stryker in Australia and New Zealand. The company also advanced its FDA regulatory pathway for its BMD module, setting sights on mid-2025 submission.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Universal Biosensors is expanding its handheld testing portfolio with the upcoming AQUASCOUT water sensor and growing sales of its FDA-approved Xprecia Prime blood coagulation device, targeting multi-billion-dollar markets.

Aroa Biosurgery has reported its first quarter of positive operating cash flow since listing on the ASX in 2020, alongside robust revenue growth projections and new regulatory approvals across key international markets.

Aurelia Metals delivers a robust December 2024 quarter, hitting key production targets and marking a milestone with first concentrate from its Federation ore. The company maintains a strong balance sheet while advancing growth projects.

Boss Energy has officially declared commercial production at its Honeymoon Uranium Project following a strong operational ramp-up, with production and cost guidance reinforcing its position as a competitive uranium producer.

4DMedical reports a remarkable 202% increase in Q2 FY2025 operating revenue, driven by rapid site expansion and key collaborations with leading healthcare providers and the U.S. Department of Defense.

MTM Critical Metals reports solid progress on its US-based Flash Joule Heating demonstration plant, targeting a Q4 2025 start-up in Texas amid favorable regulatory and funding prospects.

Sarytogan Graphite Limited has secured a key mining license and demonstrated promising product applications, supported by a significant investment from the European Bank for Reconstruction and Development. The company is progressing towards customer qualification and offtake agreements while expanding exploration efforts.